April 30 (Reuters) - Bubs Australia Ltd BUB.AX :
* ON TRACK TO EXCEED FY24 GROUP GROSS REVENUE FORECAST
* Q3 GROUP GROSS REVENUE OF A$19.9M, UP 25.9%
* REMAINS CONFIDENT IT WILL BE CASH FLOW POSITIVE AND
TRADING EBIT
POSITIVE IN FY25
* Q4 FY24 GROUP GROSS REVENUE EXPECTED TO EXCEED A$30M
* CONTINUES TO FOLLOW FDA'S GUIDANCE TO OBTAIN PERMANENT
ACCESS TO
USA IMF MARKET
* USA IMF MARKET FDA APPROVAL EXPECTED PRIOR TO OCTOBER
2025.
* CONTINUE TO SEE STRONG DEMAND FOR OUR PRODUCTS AND BRANDS
IN USA
Further company coverage: BUB.AX
((Reuters.Briefs@thomsonreuters.com;))